NCT02190227View on ClinicalTrials.gov

RNA Disruption Assay (RDA) Response Prediction in Neoadjuvant Chemotherapy Breast Cancer Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions
Invasive Breast Cancer
Interventions
DEVICE

Tumor RDA biopsy

Tumor RDA score measured from an FNA biopsy after cycle 1-2-3 of neoadjuvant chemotherapy and after first cycle of second chemotherapy agent if palpable tumour present.

Trial Locations (1)

H3T 1E2

Jewish General Hospital, Montreal

All Listed Sponsors
collaborator

Laurentian University

OTHER

lead

Jewish General Hospital

OTHER

NCT02190227 - RNA Disruption Assay (RDA) Response Prediction in Neoadjuvant Chemotherapy Breast Cancer Treatment | Biotech Hunter | Biotech Hunter